Yahoo · Oct 26, 2026
DexCom Gears Up to Report Q3 Results: How to Play the Stock?
DXCM Q3 earnings are likely to benefit from CGM adoption, G7 15 Day uptake and wider reimbursement amid tougher international comparisons.
PA
NASDAQ · PAHC
Phibro Animal Health Corporation
Healthcare · Drug Manufacturers - Specialty & Generic
$38.88
Up+$0.02 (+0.05%)
Updated Nov 2, 2026, 6:55 AM
SID Score
4.7/10
Composite research score
Smart Money
—
Institutional and insider signal
- Market cap
- 1.65B
- P/E ratio
- 24.36
- Dividend yield
- 1.23%
- 52-week range
- $28.25 – $60.08
- Volume
- 182.78K
- Avg. volume
- 292.23K
Price performance · PAHC
PAHC price history
1M range · 20 trading sessions · Daily adjusted prices
Prices through Oct 30, 2026
PAHC closed at $38.88 after 20 trading sessions, up 4.54% for the selected period.
- Last close
- $38.88
- Period change
- +4.54%
- Period low
- $36.61
- Period high
- $39.81
Daily close
View OHLC price history
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Oct 30, 2026 | $39.38 | $39.95 | $38.49 | $38.88 | 182.78K |
| Oct 29, 2026 | $38.35 | $39.01 | $38.275 | $38.86 | 100.83K |
| Oct 28, 2026 | $38.18 | $38.455 | $37.60 | $37.88 | 168.86K |
| Oct 27, 2026 | $38.95 | $39.26 | $38.30 | $38.38 | 118.87K |
| Oct 26, 2026 | $38.80 | $39.57 | $38.70 | $39.03 | 144.65K |
| Oct 23, 2026 | $39.51 | $39.51 | $38.62 | $38.80 | 102.86K |
| Oct 22, 2026 | $39.37 | $40.87 | $39.28 | $39.81 | 254.38K |
| Oct 21, 2026 | $38.74 | $39.36 | $38.11 | $39.25 | 169.2K |
| Oct 20, 2026 | $39.34 | $39.99 | $38.78 | $38.80 | 153.53K |
| Oct 19, 2026 | $39.12 | $39.81 | $38.53 | $39.34 | 184.84K |
| Oct 16, 2026 | $38.04 | $38.94 | $37.24 | $38.82 | 187K |
| Oct 15, 2026 | $38.19 | $39.64 | $37.83 | $37.98 | 184.7K |
| Oct 14, 2026 | $36.53 | $38.33 | $36.53 | $37.93 | 283.08K |
| Oct 13, 2026 | $37.75 | $37.89 | $36.70 | $36.81 | 407.39K |
| Oct 12, 2026 | $38.28 | $38.65 | $37.05 | $37.43 | 205.85K |
| Oct 9, 2026 | $37.40 | $39.255 | $37.40 | $38.30 | 235.92K |
| Oct 8, 2026 | $37.53 | $37.58 | $36.72 | $37.40 | 238.73K |
| Oct 7, 2026 | $36.43 | $37.925 | $36.03 | $37.72 | 199.53K |
| Oct 6, 2026 | $37.46 | $37.70 | $36.31 | $36.61 | 133.23K |
| Oct 5, 2026 | $37.14 | $38.05 | $37.05 | $37.19 | 280.03K |
Latest PAHC news
The latest Smart Investors Daily articles mentioning PAHC.
Stock researchCompany · Overview
Company
Market Activity
Research & News
PAHC research
Overview
Company profile and research snapshot.
Company profile
Phibro Animal Health Corp operates as a diversified animal health and mineral nutrition company. It develops, manufactures, and markets products for a range of food animals comprising poultry, swine, beef and dairy cattle, and aquaculture. The product portfolio of the company includes animal health products such as antibacterials, anticoccidials, nutritional specialty products and vaccines, and mineral nutrition products. The company operates through three segments, Animal Health, Mineral Nutrition, and Performance Products, of which key revenue is derived from the Animal Health segment which relates to the development, manufacturing, and marketing of antibacterials, nutritional specialty products, and vaccines. The entity sells its products in the U.S. and other international countries.
Visit company websiteAnalyst outlook
Consensus and target data currently published for this company.
- Consensus
- —
- Average target
- $34.00
- Implied upside
- —
- Analysts
- —
| Date | Firm | Rating | Target |
|---|---|---|---|
| May 14, 2026 | Citigroup | Neutral | — |
| Apr 15, 2026 | Citigroup | Neutral | — |
| Nov 7, 2025 | JP Morgan | Overweight | — |
| Aug 29, 2025 | B of A Securities | Underperform | — |
| Jul 7, 2025 | JP Morgan | Overweight | — |
News briefing
No generated briefing is available yet.
Yahoo · Oct 26, 2026
Will Baxter's Q3 Earnings Show Progress Despite Cost Pressures?
BAX's Q3 revenues may rise, but earnings may fall amid tariffs, manufacturing costs and infusion pump challenges. Will stronger demand offset pressures?
Yahoo · Oct 24, 2026
Phibro Animal Health (PAHC) Stock May Still Offer Value At This Price
Phibro Animal Health has seen its share price move around in recent years, and that raises a straightforward question for investors who focus on fundamentals. Is the current US$38.80 price tag adequately supported by the earnings the company is generating today? Over the past 3 years the stock has delivered a very large gain of 284.1%, which puts real pressure on the question of whether current earnings can carry that kind of re-rating. The business model is tied closely to recurring demand...
Yahoo · Oct 23, 2026
Will Phibro (PAHC) Beat Estimates Again in Its Next Earnings Report?
Phibro (PAHC) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
AI research layers
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
